Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: The EXCITE study
Ursula Schmidt-Erfurth*, Bora Eldem, Robyn Guymer, Jean Franois Korobelnik, Reinier O. Schlingemann, Ruth Axer-Siegel, Peter Wiedemann, Christian Simader, Margarita Gekkieva, Andreas Weichselberger
Research output: Contribution to journal › Article › peer-review
361Scopus
citations
Fingerprint
Dive into the research topics of 'Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: The EXCITE study'. Together they form a unique fingerprint.